Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROS-1: Zidesamtinib (NVL-520) in ROS1-positive NSCLC and other solid tumors
jRCT2031230693Phase 2Recruiting
- Sponsor
- Nuvalent
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of zidesamtinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (6 arms), sponsored by Nuvalent. Primary endpoints: Maximum tolerated dose (MTD), Recommended Phase 2 dose (RP2D) and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
zidesamtinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230693.